Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07718347

Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser

ariessence is intended to be used as a viscous, leave-on solution designed for topical application to the face. It is intended to be used following non-medical cosmetic procedures, performed by licensed healthcare professionals to enhance comfort and maintain skin hydration. This study is designed to be a multi-center, post-market cosmetic evaluation of ariessence applied to the full face after an ablative laser procedure to evaluate improvements in procedure tolerability and improvements in the appearance of the skin, compared to an emollient control.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Immediate Post-Treatment Care Aging Aging Mid-Face

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Laser & Skin Surgery Medical Group, Sacramento, California, United States

Loading trial locations.

About this study

To compare procedure tolerability of the treated facial area between ariessence and standard aftercare (Aquaphor). Tolerability, using subject tolerability assessments (subject diaries), investigator tolerability assessments, and standardized day-3/7/14 photographs, with site confirmation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-:Adults 40-65 70 years

  • Glogau III-IV
  • Fitzpatrick II-IV.
  • Suitable for ablative laser
  • non-smoker ≥ 3 years
  • Willing to comply with post-procedure regimen
  • patient reported outcome documentation, and photo documentation.

Exclusion criteria

  • Fitzpatrick I or > IV,
  • recent facial procedures (< 6 months)
  • active skin disease
  • pregnancy/lactation
  • implanted devices
  • history of keloids.

Treatment and study plan

ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).

Other

To compare time to appearance-based recovery and subject satisfaction between ariessence and standard of care groups using standardized photographs and investigator/subject ratings for tolerability and satisfaction

Primary outcomes

  1. Clinical Measures

    Time frame: Baseline (Day 0) through Day 84 (End of Study).

    Glogau Scale

  2. Patient-Reported Outcomes

    Time frame: Baseline through day 84

    FACE-Q, SKIN-Q, FACE-Q Psychological Function, treatment Discomfort/Pain Evaluation Subject Satisfaction Scale

  3. Photography

    Time frame: Baseline through Day 84

    VISIA-CR (standardized frontal ±45°), FitSkin (regional close-ups), and point-and-shoot baseline and follow-ups

  4. Investigator Objective Tolerability Assessment

    Time frame: Baseline through Day 84

    Tolerability of product

  5. Erythema grading (0-4 scale)

    Time frame: Baseline through Day 84 (End of Study)

    Degree of erthema

  6. Clinician's Global Aesthetic Improvement Scale (CGAIS).

    Time frame: Baseline through Day 84 (End of STudy)

    Measure of Aestetic Imporvement

Study contacts

Contact information is provided by the study sponsor or research team.

Josh Arnold

CONTACT

[email protected]

302-604-4532

Sponsors and collaborators

Lead sponsor

Lynch Regenerative Medicine

Network

Registry information

Official study title

A Multi-center, Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser for the Tolerability and Improvement in the Appearance of Aging Skin.

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jul 21, 2026
Registry last updated
Jul 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.